-
[show abstract]
[hide abstract]
ABSTRACT: A northern subsample of 89 Spitzer GLIMPSE extended green objects (EGOs), the
candidate massive young stellar objects, are surveyed for molecular lines in
two 1-GHz ranges: 251.5- 252.5 and 260.188-261.188 GHz. A comprehensive catalog
of observed molecular line data and spectral plots are presented. Eight
molecular species are undoubtedly detected: H13CO+, SiO, SO, CH3OH, CH3OCH3,
CH3CH2CN, HCOOCH3, and HN13C. H13CO+ 3-2 line is detected in 70 EGOs among
which 37 ones also show SiO 6-5 line, demonstrating their association to dense
gas and supporting the outflow interpretation of the extended 4.5 um excess
emission. Our major dense gas and outflow tracers (H13CO+, SiO, SO and CH3OH)
are combined with our previous survey of 13CO, 12CO and C18O 1-0 toward the
same sample of EGOs for a multi-line multi- cloud analysis of line width and
luminosity correlations. Good log-linear correlations are found among all
considered line luminosities, which requires a universal similarity of density
and thermal structures and probably of shock properties among all EGO clouds to
explain. It also requires that the shocks should be produced within the natal
clouds of the EGOs. Diverse degrees of correlation are found among the line
widths. However, both the line width and luminosity correlations tend to
progressively worsen across larger cloud subcomponent size-scales, depicting
the increase of randomness across cloud subcomponent sizes. Moreover, the line
width correlations among the three isotopic CO 1-0 lines show data scatter as
linear functions of the line width itself, indicating that the velocity
randomness also increases with whole-cloud sizes and has some regularity
behind.
07/2012;
-
Y Horikawa,
N Tsuchiya,
K Yuasa,
S Narita,
M Saito,
K Takayama,
T Nara,
H Tsuruta,
T Obara,
K Numakura, [......],
S Cai,
Z Wang,
J Xu,
W. Zhan,
Y F Zhang,
M Misumi,
H Takeuchi,
N Nakamiya,
K Matsuura,
N Fujiuchi
[show abstract]
[hide abstract]
ABSTRACT: BACKGROUND: Sunitinib is a new tyrosine kinase inhibitor that has shown significant clinical activity in metastatic renal cell carcinoma (mRCC). We are reporting early clinical experiences of sunitinib at Akita University Hospital to evaluate its efficacy and safety for Japanese RCC patients. METHODS: Between April 2006 and November 2009 at our institution, 21 patients with a median age of 61 years (range, 37 to 80 years) with mRCC were treated with sunitinib. Eleven (52.4%) patients received sunitinib as a first-line treatment. The efficacy of sunitinib was evaluated with Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. Progression-free survival (PFS) and adverse events (AEs) were assessed. RESULTS: At a median follow-up of 8 months (range, 1 to 43 months), our patients received an average of 6.2 cycles of sunitinib (range, 1 to 28 cycles). While no patients experienced complete response, partial response (PR) and stable disease (SD) were observed in 7 patients (28.5%) and 8 patients (38.0%), respectively; six patients (28.5%) had progressive disease (PD), median PFS was 10 months. The main grade 3/4 AEs were thrombocytopenia (47.6%), anemia (28.5%), leukocytopenia (19.0%), hand-foot syndrome (14.2%), and hypertension (14.2%). In addition to these AEs, hypothyroidism, which requires thyroid hormone replacement therapy, was noted in 14 (67.0%) patients. Seven patients discontinued sunitinib within 2 cycles (5 due to disease progression, 2 due to drug toxicities). Ten (66.7%) of 14 patients who received more than 3 cycles of sunitinib needed dose reduction during treatment. CONCLUSION: Sunitinib was effective for the treatment of mRCC in a real clinical setting, although there were several side effects that led to discontinuation of this drug. To utilize sunitinib safely and more effectively, further examination of this drug for Japanese RCC patients is necessary.
Japanese Journal of Clinical Oncology 03/2011; 41(3):i6-i17. · 1.78 Impact Factor
-
Annals of Oncology 07/2010; 21(7):1563-5. · 6.43 Impact Factor
-
M Kodaira, S Takahashi,
S Yamada,
K Ueda,
Y Mishima,
K Takeuchi,
N Yamamoto,
Y Ishikawa,
M Yokoyama,
T Saotome,
Y Terui,
K Hatake
[show abstract]
[hide abstract]
ABSTRACT: Cancer of unknown primary site (CUP) generally has a poor prognosis, and there is no established standard therapy. There have been no reports of a prognostic model for CUP patients treated with a single regimen of systemic chemotherapy.
Univariate and multivariate prognostic factor analysis for overall survival (OS) were conducted retrospectively in 58 consecutive CUP patients treated with carboplatin plus paclitaxel (Taxol) therapy as a first-line treatment.
Univariate prognostic factor analysis revealed baseline performance status (PS) of two or more, low serum albumin level, pleural effusion, bone metastasis, and liver metastasis as adverse prognostic factors. Cox proportional hazards analysis showed that poor PS and bone metastasis had the most powerful adverse impact on survival. We developed a prognostic model using those two variables-a good-risk group (PS 0-1 without bone metastasis) and a poor-risk group (PS > or =2 or bone metastasis). The poor-risk group showed significantly poorer OS than the good-risk group (1 year OS 36.8% versus 67.1%, P = 0.0003).
Poor PS and bone metastasis were identified as independent adverse prognostic factors in CUP. A simple prognostic model was developed and seems useful for decision making as to whether chemotherapy is indicated for CUP patients.
Annals of Oncology 12/2009; 21(6):1163-7. · 6.43 Impact Factor
-
D Ennishi,
M Yokoyama,
Y Terui,
H Asai,
S Sakajiri,
Y Mishima, S Takahashi,
H Komatsu,
K Ikeda,
K Takeuchi,
M Tanimoto,
K Hatake
[show abstract]
[hide abstract]
ABSTRACT: Soluble interleukin-2 receptor (SIL-2R) is known to be a prognostic parameter in patients with diffuse large B-cell lymphoma (DLBCL) receiving cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy. However, its prognostic value has not been well known since the introduction of rituximab.
We retrospectively evaluated the prognostic impact of SIL-2R in 228 DLBCL patients, comparing 141 rituximab-combined CHOP (RCHOP)-treated patients with 87 CHOP-treated patients as a historical control.
Patients with high serum SIL-2R showed significantly poorer event-free survival (EFS) and overall survival (OS) than patients with low SIL-2R in both the RCHOP group (2-year EFS, 66% versus 92%, P<0.001; OS, 82% versus 95%, P=0.005) and the CHOP group (2-year EFS, 40% versus 82%; OS, 61% versus 90%, both P<0.001). Multivariate analysis including the five parameters of International Prognostic Index (IPI) and two-categorized IPI revealed that SIL-2R was an independent prognostic factor for EFS and OS in the RCHOP group as well as in the CHOP group.
Our results demonstrate that SIL-2R retains its prognostic value in the rituximab era. The prognostic value of SIL-2R in DLBCL patients receiving rituximab-combined chemotherapy should be reassessed on a larger scale and by long-term follow-up.
Annals of Oncology 12/2008; 20(3):526-33. · 6.43 Impact Factor
-
D Ennishi,
K Takeuchi,
M Yokoyama,
H Asai,
Y Mishima,
Y Terui, S Takahashi,
H Komatsu,
K Ikeda,
M Yamaguchi,
R Suzuki,
M Tanimoto,
K Hatake
[show abstract]
[hide abstract]
ABSTRACT: Several biomarkers indicating poor prognosis have been reassessed in patients receiving rituximab combination chemotherapy for diffuse large B-cell lymphoma (DLBCL). However, few studies have investigated outcome in relation to a combination of these biomarkers. In addition, no large-scale studies have reassessed the outcome of patients with CD5-positive DLBCL treated with rituximab.
We conducted a retrospective study and investigated the predictive value of three biomarkers -- BCL2, germinal center (GC) phenotype and CD5 -- in 121 DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
CD5-positive patients showed significantly poorer event-free survival (EFS) and overall survival (OS) than CD5-negative patients (2-year EFS, 18% versus 73%, P < 0.001; 2-year OS, 45% versus 91%, P = 0.001). However, no significant difference in outcome according to BCL2 or GC phenotype was observed. Multivariate analysis revealed that CD5 expression was a significant prognostic factor for EFS [hazard ratio 14.2, 95% confidence interval (CI) 4.7-43.2] and OS (hazard ratio 20.3, 95% CI 3.6-114.4).
CD5 expression was the only significant prognostic factor among the biomarkers examined in this study. Further studies with larger numbers are warranted to confirm the prognostic significance of CD5 expression for patients with DLBCL receiving rituximab-containing chemotherapy.
Annals of Oncology 07/2008; 19(11):1921-6. · 6.43 Impact Factor
